ENVALITH
住友ベークライト株式会社 logo

Sumitomo Bakelite Company Limited

4203・Prime Market・Chemicals

Official website
住友ベークライト株式会社 logo
Sumitomo Bakelite Company Limited4203

Business

Sumitomo Bakelite, founded in 1955, is a manufacturer of functional chemical materials and a global group comprising 48 subsidiaries and 5 affiliates (as of the end of March 2026). Its business is organized into three segments—"Semiconductor-Related Materials," "High-Performance Plastics," and "Quality of Life-Related Products"—and it recorded revenue of ¥319,867 million (FY2026 (ending March 2026)). The company is deeply embedded in the semiconductor supply chain through products such as epoxy resin molding materials for semiconductor encapsulation, photosensitive materials, bonding paste, and substrate materials, while also offering a diverse range of products supporting daily life and industrial infrastructure, including medical devices, pharmaceutical packaging, waterproof sheets, and aircraft parts. With production and research facilities across Asia, Europe, and the Americas, the company invests ¥13,300 million in R&D, focusing on ICT, mobility, and healthcare as its three strategic areas.

Business Model

The company operates a B2B business model, manufacturing in-house developed functional resins, films, and medical materials, and selling them to semiconductor manufacturers, automotive parts manufacturers, medical device manufacturers, and others. Under its medium-term policy of capturing the top share in niche markets, it is improving its earnings structure through a shift toward high value-added products and appropriate pricing. It has set a capital expenditure budget of ¥50.0 billion, a strategic investment budget of ¥50.0 billion, and a growth investment budget of ¥20.0 billion (over the three-year medium-term period), and will continue to expand its business portfolio through a combination of M&A and in-house investment.

Company Strengths

The company holds a product portfolio spanning the entire semiconductor manufacturing process, including encapsulants, photosensitive materials, bonding paste, and LαZ® substrate materials. In FY2026 (ending March 2026), the Semiconductor-Related Materials segment achieved revenue of ¥106,396 million and a business profit margin of 19.5%, recording a 16.5% year-on-year increase in revenue and a 15.2% increase in profit. The company has production and research bases in China, Taiwan, Singapore, and elsewhere, building a global supply framework.

As of the end of FY2026 (ending March 2026), the equity attributable to owners of the parent ratio exceeded 70%, and net cash remained positive at over ¥90 billion. Against total assets of ¥484,167 million, total liabilities stood at ¥133,521 million, indicating low leverage. While conducting capital expenditure of ¥19,276 million primarily through internal funds, the company maintains the financial flexibility to nimbly execute M&A activities (such as the polycarbonate business and the takeover of Kyocera Chemical's business).

In addition to the Advanced Materials Research Laboratory, the Bioscience Research Laboratory, and five product-specific research laboratories, the company operates research facilities both domestically and overseas, including Promerus LLC in the United States. R&D expenses for FY2026 (ending March 2026) totaled ¥13,300 million, during which the company developed and launched a total of 18 products, including PDMS-free epoxy encapsulants for AI applications and high-thermal-conductivity substrate materials for power semiconductors. A mass-production preparation project for anion exchange membranes for hydrogen production was also launched, laying the groundwork for next-generation materials.

ENVALITH's Perspective

In FY2025 (ended March 2025), special expenses including an impairment loss (¥4,211 million) recorded at the North American base of the High-Performance Plastics segment and domestic production base consolidation costs weighed on results; with these falling away, operating profit for FY2026 (ending March 2026) recovered sharply to ¥35,478 million (up 43.1% year on year). The increase in operating profit, which far exceeds the growth in business profit (up 11.8%), is largely attributable to temporary rebound factors, and the FY2027 (ending March 2027) operating profit forecast of ¥37,500 million (up 5.7% year on year) diverges from the business profit growth rate (up 10.2%), making it important to assess the normalized profit level.

In FY2026 (ending March 2026), the Semiconductor-Related Materials segment's revenue was ¥106,396 million, accounting for approximately 33% of the company total, and on a business profit basis, it contributed ¥20,714 million, or approximately 52% of the total segment sum (¥39,919 million). Revenue from China reached ¥69,460 million (21.7% of company total), up 11.5% year on year, and the impact on performance should geopolitical risks such as US-China trade friction or tightened export controls materialize is closely watched as the largest downside risk.

Cash flow from operating activities in FY2026 (ending March 2026) was ¥35,003 million, down ¥8,708 million from the prior period (¥43,711 million). Despite the increase in profit before tax, this decline was driven by an increase in income tax payments (from ¥8,040 million to ¥10,280 million) and an increase in working capital. Meanwhile, share buybacks shrank sharply from ¥20,018 million in the prior period to ¥7 million, while the annual dividend was raised to ¥110 (from ¥95 in the prior period). ROE (profit for the period attributable to owners of the parent divided by equity attributable to owners of the parent) improved to 8.8% from 6.5% in the prior period, and continued improvement in capital efficiency will be required.

Growth Strategy

Concentrated investment in semiconductor, medical, and environmental fields under a niche-and-top-share strategy to upgrade the portfolio

Promoting expanded adoption of the LαZ® Series in power devices for AI servers, expansion of Bonding Paste for Semiconductors into high-density packaging applications in Southeast Asia, and expanded sales of photosensitive materials for power semiconductor applications. Optimizing the supply system by leveraging the new plant in China and new production line in Taiwan to meet robust demand. Achieved revenue of ¥106,396 million and a business profit margin of 19.5% in FY2026 (ending March 2026).

Implementing withdrawal from unprofitable products at North American sites and consolidation of domestic production sites, promoting fixed cost reductions and a shift toward high-value-added products. Achieved business profit of ¥6,224 million (up 18.4% year on year) in FY2026 (ending March 2026), with the effects of structural reform beginning to appear in the results. Orders for aircraft parts increased due to a recovery in customers' production volumes.

Promoting growth in domestic and overseas sales of medical devices (micro active catheters and thoracic stent grafts), expansion of applications for Films & Sheets in pharmaceutical packaging and semiconductor production, and capturing demand for building materials including hollow polycarbonate acquired through business transfer. Achieved a 9.5% increase in business profit through selling price optimization and fixed cost reductions from production site reorganization.

As the final year of the medium-term plan that started in fiscal 2024, aiming for product portfolio transformation in each business division and early realization of synergies from acquired businesses (including the Kyocera Chemical business). Goodwill in FY2026 (ending March 2026) increased to ¥3,216 million (from ¥1,494 million in the previous fiscal year), reflecting ongoing incorporation of acquisition effects.

Last updated: July 19, 2026